TD Cowen initiated coverage of Globus Medical (GMED) with a Buy rating and $110 price target The stock has overcome a lot of negative sentiment, and while many investors now appreciate the long-tailed earnings power story, there is still room for outperformance, the analyst tells investors in a research note. Enabling Tech/Intenational/Nevro have wood-to-chop, but the firm is confident Globus Medical can affect change, resulting in the potential for out-year, DD top-line growth and multiple expansion, TD Cowen added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- TD Cowen Initiates Globus Medical with Buy Rating on Durable U.S. Spine Growth and Upside from Margin Expansion
- Globus Medical price target raised to $112 from $105 at Canaccord
- Video: Defense stocks boosted by Trump budget request
- Globus Medical price target raised to $115 from $90 at Piper Sandler
- Globus Medical: Strong Execution and Upside Revisions Balanced by Full Valuation Support Hold Rating